Home/Pipeline/VK2735 (subcutaneous)

VK2735 (subcutaneous)

Obesity

Phase 3Active

Key Facts

Indication

Obesity

Phase

Phase 3

Status

Active

Company

Viking Therapeutics

About Viking Therapeutics

Viking Therapeutics leverages its expertise in metabolism to develop innovative therapies for metabolic and endocrine disorders. The company's most advanced program, VK2735, is a dual GLP-1/GIP receptor agonist currently in Phase 3 trials for obesity, with promising Phase 2 data showing significant weight reduction. Viking is also developing VK2809 for lipid disorders and maintains a broader pipeline including VK0214 and VK5211, positioning itself as a key player in the competitive metabolic disease space.

View full company profile

Therapeutic Areas

Metabolic Disorders Endocrine Disorders Obesity Lipid Disorders

Other Obesity Drugs

Drug	Company	Phase	Status
Tirzepatide (Zepbound)	Eli Lilly	Approved	Commercial
APJ Program	BioAge Labs	Preclinical	Active
Wegovy HD (semaglutide 7.2mg)	Novo Nordisk	Approved	Recently approved in US
Amylin analogue (subcutaneous)	Novo Nordisk	Phase 1	Active
GLP1-GIP-Amylin tri-agonist	Novo Nordisk	Phase 2	Active
VK2735 (oral)	Viking Therapeutics	Phase 1/2	Active
GSBR-1290	Structure Therapeutics	Phase 2	Active, not recruiting
LTSE-2578	Structure Therapeutics	Preclinical	Lead Optimization
Survodutide (BI 456906)	Zealand Pharma	Phase 3	Active
ZP8396	Zealand Pharma	Preclinical/Phase 1	Active
Pemvidutide (ALT-801)	Altimmune	Phase 2	Active
PL7737	Palatin Technologies	Preclinical	Active